VEGFA and neoplasm: Tailoring of chemotherapy drugs to tumor histology [6] and addition of anti-VEGF for nonsquamous NSCLC [41] are the major changes in chemotherapy choices that entered practice during 2000–2010; each of these had been demonstrated to improve median survival of clinical trial patients.